Chief Scientific Officer @AdicetBio. #CART #TcellRx #TCR #gammadelta #immunotherapy ... Tweets are my own; retweets are not endorsements
Joined September 2010
- Tweets 497
- Following 144
- Followers 209
- Likes 1,290
36 Photos and videos
Blake Aftab Ph.D. retweeted
Dear biologists, what would you be willing to pay for this service?👇
If you've got raw RNAseq data - can be 10 or can be a 1,000 samples, then we can provide a comprehensive analysis of the data in real fast time, like within 2-3 days.
Details 👇
3
16
28
12,535
Blake Aftab Ph.D. retweeted
3 Mar 2023
We are pleased to announce Shon Green, Ph.D, as our new Vice President of Nonclinical Development! Shon will play a crucial role as we advance our novel pipeline of CAR and CAd gamma delta T cell therapies. #biotechnology #celltherapy #CART #oncology
2
4
782
Blake Aftab Ph.D. retweeted
23 Feb 2023
The latest issue of Blood is now available featuring a new review series on banked allogeneic immune effector cells. Also, a bonus podcast episode discussing the series with Associate Editor Dr. Helen Heslop and author Dr. Jeffery Miller. loom.ly/p1Ds0qA
7
17
7,578
Blake Aftab Ph.D. retweeted
27 Jan 2023
Please RT. Abstract submission for APVIC 2023 meeting is due by Feb 15. Don't forget register for the meeting as well. You can see more details on apvic.org/ @APVICongress @ASImmunology @QIMRBerghofer @WEHI_research @TheDohertyInst @TRI_info @ClinTransImmuno
8
8
1,770
Blake Aftab Ph.D. retweeted
12 Jan 2023
Registration and abstract submission for Asia Pacific Vaccine and Immunotherapy Congress is open apvic.org/ Amazing list of speakers: apvic.org/invited-speakers @QIMRBerghofer @ClinTransImmuno @ASImmunology @TRI_info @YUmmunology @MelbImmunoNet @UQ_News @TheDohertyInst
3
6
829
Blake Aftab Ph.D. retweeted
10 Dec 2022
@AdicetBio announces positive clinical data including continued complete responses across dose levels and six-month durability for ADI-001 at #ASH2022!
investor.adicetbio.com/news-…
#celltherapy #CART #biotechnology #oncology
3
6
Blake Aftab Ph.D. retweeted
Best of @ClinTransImmuno at #ASI2022Mel first up is @K_P_Nishimoto @AdicetBio describing their study published-
'Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models.'
onlinelibrary.wiley.com/doi/… @ASImmunology
2
7
11 Nov 2022
Couldn't be more proud of our scientists and our #team for what they are accomplishing with the strength of their science. #sitc2022
11 Nov 2022
Congratulations to Marissa Herrman & the Adicet research team for being selected as this year’s @jitcancer Best Immune Cell Therapies and Immune Cell Engineering Paper! Your commitment to developing transformative therapies to defeat cancer is inspiring! #celltherapy #SITC2022
1
Blake Aftab Ph.D. retweeted
9 Nov 2022
Join us tomorrow (Thursday, Nov 10 at 9:00 a.m. ET) for our R&D Day where we’ll be unveiling details on four new highly differentiated CAR and CAd pipeline candidates! Live Webcast link in Investor “Presentations & Events” section at adicetbio.com.
1
1
2
Blake Aftab Ph.D. retweeted
8 Nov 2022
Adicet is excited to be on the ground @sitcancer kicking off today in Boston! We’re presenting preclinical data and unveiling 4 new highly differentiated CAR (chimeric antigen receptor) and CAd (chimeric adaptor) pipeline programs targeting several heme and solid malignancies.
3
4
Blake Aftab Ph.D. retweeted
31 Oct 2022
Early use of third-party virus-specific T-cells is safe and leads to high rates of viral control and excellent outcomes in HSCT. loom.ly/eW36rVY #immunobiologyandimmunotherapy
6
12
Blake Aftab Ph.D. retweeted
13 Sep 2022
Why $ACET is moving quickly with its cell therapy against non-Hodgkin's lymphoma — and taking more space #biotech bizjournals.com/sanjose/news…
1
1
Blake Aftab Ph.D. retweeted
20 Aug 2022
As our pipeline progresses, we expanded into a new state-of-the-art facility! We look forward to calling this home as we live our mission to deliver best-in-class gamma delta T cell therapies for patients fighting cancer! #Adicetlife #greatplacetowork #celltherapy #biotechnology
3
3
Blake Aftab Ph.D. retweeted
5 Jul 2022
Presence of gamma-delta1 T cells is strongly associated with survival of patients with Non-Small Cell Lung Cancer and several additional solid tumors. Check recent nature cancer publication June 2022.
1
1
2
Blake Aftab Ph.D. retweeted
30 Jun 2022
Another reminder for upcoming ANZ ISCT meeting in Brisbane on Aug 4-5, 2022. Check this link for more details: bit.ly/3a0AmJs @ISCTglobal @celltherapynews @celltherapyblog @CellTherapies_ @ZlatiborVelick1 @EmilyBlyth5 @jmacpher @ngaire_elwood @KlamerGuy
7
11
Blake Aftab Ph.D. retweeted
17 Jun 2022
We’re celebrating #pride at @Adicet and recognizing the important role the LGBTQ community has played in building diverse, inclusive and supportive communities. There is more work to be done and we continue to listen, learn and support advances in #diversityandinclusion.
2
2
Blake Aftab Ph.D. retweeted
16 Jun 2022
The Miles lab is hiring and our first job post is live!! We are looking for an excited, passionate research assistant to join our new team. Please retweet and share with anyone interested!
Research Assistant II/III/IV – Linde Miles Lab (@lindemilesphd)
Cincinnati Children's Hospital Medical Center (@CincyChildrens) - The Miles Lab - USA
jobrxiv.org/job/cincinnati-c…
#ScienceJobs
2
42
87
Blake Aftab Ph.D. retweeted
9 Jun 2022
We're closing the day at the @NasdaqExchange with @AdicetBio! 🧬
$ACET is a clinical stage biotechnology company discovering and developing allogeneic gamma-delta T cell therapies for cancer.
3
14
Blake Aftab Ph.D. retweeted
9 Jun 2022
On the heels of an exciting ASCO where we presented additional positive data on ADI-001, the team rang the closing bell at NASDAQ today!! It’s an honor to see so many inspired by our mission to deliver best-in-class gamma-delta T cell therapies for patients fighting cancer.
9 Jun 2022
We're closing the day at the @NasdaqExchange with @AdicetBio! 🧬
$ACET is a clinical stage biotechnology company discovering and developing allogeneic gamma-delta T cell therapies for cancer.
1
3
